# Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL

> **NCT05441761** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Treatment
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin

## Key facts

- **NCT ID:** NCT05441761
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441761, "Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05441761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*